Relay Therapeutics, Inc. (RLAY) Stock Grade

About Relay Therapeutics, Inc.'s fundamentals

Relay Therapeutics is a biotechnology company with a market capitalization of $3.9 billion that is currently unprofitable, reporting a net loss and a net margin of -1800.6% in its latest annual statement. The company demonstrated strong revenue growth of 53.4% year-over-year, indicating expanding commercial activity or clinical progress. As a loss-making biotech firm with no dividend, the company is reinvesting resources into research and development rather than returning capital to shareholders. Traditional valuation metrics like P/E ratio and return on equity are not applicable given the company's current unprofitable status.